Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease☆

Understanding the sequence of biological and clinical events along the course of Alzheimer's disease provides insights into dementia pathophysiology and can help participant selection in clinical trials. Our objective is to train two data-driven computational models for sequencing these events, the Event Based Model (EBM) and discriminative-EBM (DEBM), on the basis of well-characterized research data, then validate the trained models on subjects from clinical cohorts characterized by less-structured data-acquisition protocols. Seven independent data cohorts were considered totalling 2389 cognitively normal (CN), 1424 mild cognitive impairment (MCI) and 743 Alzheimer's disease (AD) patients. The Alzheimer's Disease Neuroimaging Initiative (ADNI) data set was used as training set for the constriction of disease models while a collection of multi-centric data cohorts was used as test set for validation. Cross-sectional information related to clinical, cognitive, imaging and cerebrospinal fluid (CSF) biomarkers was used. Event sequences obtained with EBM and DEBM showed differences in the ordering of single biomarkers but according to both the first biomarkers to become abnormal were those related to CSF, followed by cognitive scores, while structural imaging showed significant volumetric decreases at later stages of the disease progression. Staging of test set subjects based on sequences obtained with both models showed good linear correlation with the Mini Mental State Examination score (R2EBM = 0.866; R2DEBM = 0.906). In discriminant analyses, significant differences (p-value ≤ 0.05) between the staging of subjects from training and test sets were observed in both models. No significant difference between the staging of subjects from the training and test was observed (p-value > 0.05) when considering a subset composed by 562 subjects for which all biomarker families (cognitive, imaging and CSF) are available. Event sequence obtained with DEBM recapitulates the heuristic models in a data-driven fashion and is clinically plausible. We demonstrated inter-cohort transferability of two disease progression models and their robustness in detecting AD phases. This is an important step towards the adoption of data-driven statistical models into clinical domain.

[1]  Stanley Durrleman,et al.  Learning spatiotemporal trajectories from manifold-valued longitudinal data , 2015, NIPS.

[2]  Massimo Filippi,et al.  The European DTI Study on Dementia — A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment , 2017, NeuroImage.

[3]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[4]  A. Siderowf,et al.  Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease , 2009, Neurology.

[5]  David Manset,et al.  Virtual imaging laboratories for marker discovery in neurodegenerative diseases , 2011, Nature Reviews Neurology.

[6]  Daniel C Alexander,et al.  Data-driven models of dominantly-inherited Alzheimer’s disease progression , 2018, bioRxiv.

[7]  Stefan Klein,et al.  A Discriminative Event Based Model for Alzheimer's Disease Progression Modeling , 2017, IPMI.

[8]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[9]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[10]  Dinggang Shen,et al.  Deep Learning Based Imaging Data Completion for Improved Brain Disease Diagnosis , 2014, MICCAI.

[11]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[12]  J. Trojanowski,et al.  Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. , 2012, Methods.

[13]  L. Vécsei,et al.  Male brain ages faster: the age and gender dependence of subcortical volumes , 2016, Brain Imaging and Behavior.

[14]  J. Kulisevsky,et al.  Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging , 2003, International journal of geriatric psychiatry.

[15]  Timo Grimmer,et al.  Mapping scores onto stages: mini-mental state examination and clinical dementia rating. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[16]  J. Schneider,et al.  Overview and findings from the rush Memory and Aging Project. , 2012, Current Alzheimer research.

[17]  Frederik Barkhof,et al.  Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment , 2017, Alzheimer's Research & Therapy.

[18]  G. Frisoni,et al.  Markers of Alzheimer's disease in a population attending a memory clinic , 2009, Alzheimer's & Dementia.

[19]  Wiro J. Niessen,et al.  Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling , 2018, NeuroImage.

[20]  Self-Concept Variables.  Sex Differences in , 2016 .

[21]  S. Allassonnière,et al.  Spatiotemporal Propagation of the Cortical Atrophy: Population and Individual Patterns , 2018, Front. Neurol..

[22]  Nick C Fox,et al.  A data-driven model of biomarker changes in sporadic Alzheimer's disease , 2014, Alzheimer's & Dementia.

[23]  G. Schellenberg,et al.  Dementia and Alzheimer disease incidence: a prospective cohort study. , 2002, Archives of neurology.

[24]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[25]  Nick C Fox,et al.  Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference , 2017, Nature Communications.

[26]  G. Bloom.  Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. , 2014, JAMA neurology.

[27]  J. Butler.  Enzyme-Linked Immunosorbent Assay , 2000, Journal of immunoassay.

[28]  R. Gur,et al.  Gender differences in age effect on brain atrophy measured by magnetic resonance imaging. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Baxter,et al.  Sex differences on the Rey Auditory Verbal Learning Test and the Brief Visuospatial Memory Test–Revised in the elderly: Normative data in 172 participants , 2007, Journal of clinical and experimental neuropsychology.

[30]  Frederik Barkhof,et al.  Optimizing patient care and research: the Amsterdam Dementia Cohort. , 2014, Journal of Alzheimer's disease : JAD.

[31]  Nicholas C. Firth,et al.  Progression of regional grey matter atrophy in multiple sclerosis , 2017, bioRxiv.

[32]  J. Morris,et al.  Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans , 2010, Alzheimer's & Dementia.

[33]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[34]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[35]  S. Hawkins,et al.  Disease Progression , 2020, Definitions.

[36]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[37]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[38]  Maurizio Filippone,et al.  Probabilistic disease progression modeling to characterize diagnostic uncertainty: Application to staging and prediction in Alzheimer's disease , 2017, NeuroImage.

[39]  Joylee Wu,et al.  The National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data Set , 2007, Alzheimer disease and associated disorders.

[40]  C. Jack,et al.  Role of structural MRI in Alzheimer's disease , 2010, Alzheimer's Research & Therapy.

[41]  John G. Csernansky,et al.  Open Access Series of Imaging Studies (OASIS): Cross-sectional MRI Data in Young, Middle Aged, Nondemented, and Demented Older Adults , 2007, Journal of Cognitive Neuroscience.

[42]  Tristan Glatard,et al.  Head-to-Head Comparison of Two Popular Cortical Thickness Extraction Algorithms: A Cross-Sectional and Longitudinal Study , 2015, PloS one.

[43]  T. Tombaugh,et al.  The Mini‐Mental State Examination: A Comprehensive Review , 1992, Journal of the American Geriatrics Society.

[44]  Norbert Schuff,et al.  Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis , 2016, Nature Communications.

[45]  J. Molinuevo,et al.  MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study , 2018, Alzheimer's Research & Therapy.

[46]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[47]  Sébastien Ourselin,et al.  Multiple Orderings of Events in Disease Progression , 2015, IPMI.

[48]  Neil P. Oxtoby,et al.  Imaging plus X: multimodal models of neurodegenerative disease , 2017, Current opinion in neurology.

[49]  H. Braak,et al.  Staging of Alzheimer-related cortical destruction. , 1997, International psychogeriatrics.

[50]  J. Schneider,et al.  Overview and findings from the religious orders study. , 2012, Current Alzheimer research.

[51]  David Manset,et al.  Brain investigation and brain conceptualization. , 2013, Functional neurology.

[52]  Luc Buée,et al.  A new decision tree combining Abeta 1-42 and p-Tau levels in Alzheimer's diagnosis. , 2013, Current Alzheimer research.

[53]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[54]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[55]  Sébastien Ourselin,et al.  An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease , 2012, NeuroImage.

[56]  P. Fischer,et al.  Vienna Transdanube Aging "VITA": study design, recruitment strategies and level of participation. , 2002, Journal of neural transmission. Supplementum.

[57]  Jerry L. Prince,et al.  A computational neurodegenerative disease progression score: Method and results with the Alzheimer's disease neuroimaging initiative cohort , 2012, NeuroImage.

[58]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[59]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[60]  Hélène Jacqmin-Gadda,et al.  Estimating long-term multivariate progression from short-term data , 2014, Alzheimer's & Dementia.

[61]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[62]  Nicholas C. Firth,et al.  An image‐based model of brain volume biomarker changes in Huntington's disease , 2018, Annals of clinical and translational neurology.

[63]  Nick C Fox,et al.  Secondary prevention of Alzheimer’s dementia: neuroimaging contributions , 2018, Alzheimer's Research & Therapy.

[64]  J. Molinuevo,et al.  Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a ‘European ADNI study’ , 2016, Journal of internal medicine.

[65]  V. Calhoun,et al.  Prognostic classification of mild cognitive impairment and Alzheimer׳s disease: MRI independent component analysis , 2014, Psychiatry Research: Neuroimaging.